

Evolution of Patient Perceptions of Psoriatic Disease: Results From the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey

Mark Lebwohl¹; Richard G. Langley²; Carle Paul³; Lluís Puig⁴; Kristian Reich⁵; Peter van der Kerkhof⁶; Lihua Tang⁷; Sven Richter⁷; Benoit Guérette⁷; Paolo Gisondi⁸
¹Icahn School of Medicine at Mount Sinai, New York, NY, USA; ²Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, Canada; ³Paul Sabatier University, Toulouse, France; ⁴Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; ⁵Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ⁶Department of Dermatology, Radboud University Medical Center, Nijmegen, Netherlands; ⁷Amgen Inc., Thousand Oaks, CA, USA; ⁸University Hospital of Verona, Verona, Italy

Synopsis

- The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey provided valuable data on quality of life and unmet needs in patients with psoriasis (PsO) and/or psoriatic arthritis (PsA)^{1,2}
- Since the 2012 MAPP survey, PsO treatment options have increased^{1,3-5}
- The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey was designed to better understand how perspectives on treatment-related outcomes have evolved since the MAPP survey, particularly for patients with mild to moderate disease. We present patient-reported data from UPLIFT and MAPP
- More than half of patients in the UPLIFT survey perceived their current PsO symptoms as moderate or severe despite limited skin involvement. Additionally, many patients were not receiving any medication, suggesting that there remains significant unmet need

Objective

- The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey was designed to better understand how perspectives on treatment-related outcomes have evolved since the MAPP survey, particularly for patients with mild to moderate disease. We present patient-reported data from UPLIFT and MAPP

Methods


- UPLIFT:** Quantitative online survey from March 2, 2020, to June 3, 2020
 - 4,729 participants (473 dermatologists, 450 rheumatologists, 3,806 patients)
- MAPP:** Telephone survey from June 2012 to August 2012^{1,2,6}
 - 4,207 participants (391 dermatologists, 390 rheumatologists, 3,426 patients)^{1,2,6}
- Both studies included adult patients (≥18 years of age) who reported that they had been diagnosed with PsO and/or PsA by a healthcare practitioner




Results

- In both UPLIFT and MAPP:
- Most patients had PsO
 - Similar proportions of patients reported having limited skin involvement (body surface area [BSA] ≤3 palms)

Diagnosis



Self-reported PsO Severity




More than half of UPLIFT patients with limited BSA (≤3 palms) perceived their PsO as moderate or severe

- In UPLIFT, 58% of patients with limited BSA rated their current PsO symptoms as moderate or severe
- Many had PsO involvement in special areas (scalp, face, palms and/or soles, nails, genitals) and were not receiving treatment

In UPLIFT, 60% of PsO patients with limited BSA and involvement in ≥1 special area reported their current disease as moderate or severe

Of these, 51% were receiving topicals or no treatment

In both surveys, high proportions of patients reported that they were not currently receiving treatment



Conclusion

- More than half of patients with limited skin involvement reported their current disease as moderate or severe, had PsO involvement in special areas, and were receiving topicals or no treatment, suggesting a persistent unmet need in this patient population
- In MAPP vs. UPLIFT, the proportion of patients describing their disease as moderate to severe on systematic treatment remained relatively low despite the higher number of available treatment options
- Further research is needed to better understand why a significant proportion of patients with limited skin involvement and PsO in special areas perceive their current disease as moderate or severe but do not receive systemic treatment


Results

Patients in UPLIFT had higher rates of certain comorbidities but lower mean age vs. patients in MAPP

	UPLIFT N = 3,806	MAPP N = 3,426
Age, years, mean	45.1	54.8
Female, n (%)	1,892 (49.7)	2,026 (59.1)
Comorbidities, n (%)		
Arthritis*	1,157 (30.4)	1,179 (34.4)
Cancer	693 (18.2)	189 (5.5)
Depression	1,257 (33.0)	626 (18.3)
Diabetes	903 (23.7)	489 (14.3)
Heart disease	520 (13.7)	345 (10.1)
Hypertension	1,342 (35.3)	1,121 (32.7)
Inflammatory bowel disease†	512 (13.5)	129 (3.8)
Liver disease	419 (11.0)	71 (2.1)

N represents the total sample. The number of patients with data available may vary. *Osteoarthritis or rheumatoid arthritis in UPLIFT and any arthritis in MAPP. †Crohn's disease and ulcerative colitis.

PsO in special areas was commonly reported in both surveys.* In UPLIFT, >50% of patients had scalp involvement



*Among patients with PsO and presence of skin symptoms. †Soles of feet in UPLIFT; soles in MAPP. Note: A patient may have more than one special area.

Disclosures & Funding Statement

ML: Mount Sinai – employment; AbbVie, Amgen Inc., Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB – research funds; Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy's Laboratories, Serono, Theravance, and Verica – consultant. **RL:** AbbVie, Amgen Inc., Boehringer Ingelheim, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, and UCB – principal investigator, scientific advisory board, or speaker. **CP:** No conflicts to disclose. **LP:** AbbVie, Amgen Inc., Boehringer Ingelheim, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB – fees; AbbVie, Almirall, Amgen Inc., Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, LEO Pharma, Lilly, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB – honoraria and consultant fees; Celgene, Janssen, Lilly, MSD, Novartis, and Pfizer – company-sponsored speakers bureaus. **KR:** AbbVie, Affibody, Almirall, Amgen Inc., Avillion, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Covagen, Dermira, Forward Pharma, Fresenius Medical Care, Galapagos, GlaxoSmithKline, Janssen-Cilag, Kyowa Kirin, Leo, Lilly, Medac, Merck Sharp & Dohme, Novartis, Miltenyi Biotec, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB, Valeant, and Xenopt – paid speaker and/or participated in clinical trials. **PdK:** AbbVie, Almirall, Bristol-Myers Squibb, Celgene, Dermavant, Eli Lilly, Janssen, LEO Pharma, and Novartis – consultant and/or lecturer. **LT, SR, & BG:** Amgen Inc. – employment. **PG:** AbbVie, Amgen Inc., Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB – consultant and grant/research support. **Funding Statement:** This survey was funded by Amgen Inc. Writing support was funded by Amy Shaberman, PhD, of Peloton Advantage, LLC, an OPEN Health company.

1. Lebwohl MG, et al. *J Am Acad Dermatol*. 2014;70:871-881. 2. van de Kerkhof PC, et al. *J Eur Acad Dermatol Venereol*. 2015;29:2002-2010. 3. Oetzi [package insert]. Thousand Oaks, CA: Amgen, Inc.; 2020. 4. Ilumya [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2016. 5. Tremfya [package insert]. Horsham, PA: Janssen Biotech, Inc; 2017. 6. Lebwohl MG, et al. *Am J Clin Dermatol*. 2016;17:87-97.